Sanofi's single-molecule problem

On the thirteenth of each month Sanofi, a French pharmaceutical group, files the corporate equivalent of a formality: the number of its shares and voting rights. The record for July showed 1,207,773,393 issued shares and 1,336,308,574 "real" voting rights. The disparity is French law at work, doubling the vote of shares held in registered form for two years or more, and thus handing control to the durable holder. Yet the disclosure, dull to the point of invisibility, hides the company's true condition. Sanofi is a business that grows because of one molecule, and little else.

Consider the second quarter. Sales rose 17.8% at constant exchange rates to €11.6bn, and management raised its full-year forecast to growth of about 10%. The engine is Dupixent, a treatment for asthma and eczema that crossed €5bn of quarterly sales for the first time, up 37.6%. The dependence is starkest in the first quarter's accounts: Dupixent accounted for 40% of total revenue then, and the drug's €690m of additional sales exceeded the whole company's €614m of growth. Strip out Dupixent and Sanofi shrank.

This is the familiar shape of blockbuster addiction. The patent on Dupixent's active ingredient expires in the United States in March 2031. Sanofi speaks of a "vigorous defence" — a four-weekly reformulation and new patents that it hopes could stretch protection towards 2045 — but that postpones, rather than removes, the deadline. However the lawyers engineer it, sometime in the next decade the molecule that is now roughly two-fifths of revenue will meet cheap copies. Everything else about the firm is a long bet on filling that hole.

The reckoning, and the rents

The response is being run by a new chief executive, Belén Garijo, who took over in February after the board declined to renew Paul Hudson's mandate. Her first act has been a pipeline reckoning. Sanofi has dropped its experimental eczema drug amlitelimab from global regulatory submission despite positive phase-3 results, and shelved itepekimab and balinatunfib. The urge to prune is understandable: money spent on a marginal hope is money not spent on a credible successor. Garijo's own targets give the game away — Dupixent to roughly €25bn by 2030, plus another €10bn from newer launches such as Ayvakit, ALTUVIIIO and Sarclisa. Those are ambitions, not achievements, and they carry the whole argument.

The market's scepticism shows in the equity. AInvest's aggregate signal labels the shares "Hold" even as its own fundamental score rates the company highly. The incongruity prices the real risk: this is a strong business resting on a single, threatened product. Its capital-return behaviour is equally two-faced. The dividend of €4.12 a share, raised for the thirty-first consecutive year and yielding around 5%, confirms a mature cash machine. The €1bn share buyback, which quietly retired about 1.05% of the equity in the second quarter, is more gesture than transformation. Sanofi is profitable enough to pay its owners generously and uncertain enough about the future to want to keep the money in hand — the share count barely moves.

What the numbers will not say

The month-by-month count of shares has, in that sense, already told its story. It recounts a company keeping shareholders happy with buybacks and dividends while its share of the voting rights migrates to long-term holders, who are left to carry the risk the executives admit exists. The institution is intact; the product is the problem.

Sanofi has the advantage most industrial groups lack — a durable monopoly and the cash it spins off — and the disposal of Opella, its consumer-health arm, has made it a cleaner bet on prescription drugs. The investment question is not whether the company is good; by most measures it is, and the market knows its fundamental strength. It is whether Garijo can turn Dupixent's rents into replacements before the cliff arrives. Today's record earnings describe yesterday's success. The verdict on her tenure will be written by whatever she brings to market before 2031, and no dutiful monthly disclosure will settle it in advance.